Ebreichsdorf, Austria

Harald Engelhardt

USPTO Granted Patents = 24 



Average Co-Inventor Count = 3.7

ph-index = 8

Forward Citations = 216(Granted Patents)


Location History:

  • Ingelheim am Rhein, DE (2013)
  • Eberichsdorf, AT (2015)
  • Ebreichsdorf, AU (2016)
  • Ebreichsdorf, AT (2007 - 2024)

Company Filing History:


Years Active: 2007-2024

Loading Chart...
Loading Chart...
Loading Chart...
24 patents (USPTO):Explore Patents

Sure, here is the article about inventor Harald Engelhardt:

Title: The Innovative Mind of Harald Engelhardt in Ebreichsdorf, AT

Introduction:

Harald Engelhardt is a prolific inventor based in Ebreichsdorf, AT, with an impressive track record of 23 patents to his name. His groundbreaking work has significantly influenced the field of pharmaceuticals, particularly in the treatment and prevention of oncological diseases.

Latest Patents:

Engelhardt's latest patents include two significant innovations. The first is related to "Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors," showcasing his expertise in developing compounds that inhibit HER2 and its mutants. The second patent focuses on "[1,6]naphthyridine compounds and derivatives as CDK8/CDK19 inhibitors," highlighting his dedication to creating novel solutions for the treatment of oncological diseases.

Career Highlights:

Harald Engelhardt is a valued member of the research and development team at Boehringer Ingelheim International GmbH. Through his innovative approach and dedication to scientific advancement, he has played a vital role in shaping the company's success in the pharmaceutical industry.

Collaborations:

Engelhardt has collaborated with esteemed colleagues such as Heinz Stadtmueller and Christian Smethurst. Together, they have contributed to revolutionary discoveries and have collectively advanced the boundaries of pharmaceutical research.

Conclusion:

In conclusion, Harald Engelhardt's contributions to the field of pharmaceuticals are truly remarkable. His inventive spirit and collaborative efforts continue to drive groundbreaking innovations in the development of novel medicaments for the treatment and prevention of oncological diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…